Recurrent Miscarriage Signs: When to See a Doctor

What Counts as Recurrent Miscarriage, and Why the Definition Matters

Recurrent pregnancy loss (RPL) is defined by most major guidelines as two or more failed clinical pregnancies before 20 weeks of gestation. The American Society for Reproductive Medicine (ASRM) uses this two-loss threshold, while the older three-loss definition is now largely abandoned because waiting for a third loss delays investigation and causes unnecessary harm.

The distinction matters for you practically. If you have had two losses, you qualify for a diagnostic workup now. You do not need to wait for a third.

The word "consecutive" also matters. Two losses in a row are treated differently from two losses separated by a successful pregnancy, though any pattern of repeated loss deserves conversation with a specialist.

What Counts as a Clinical Pregnancy

A clinical pregnancy is one confirmed by ultrasound or histopathology, not just a positive home test. Biochemical pregnancies, where a blood or urine test turns positive but no sac is ever seen on ultrasound, are typically not counted in the RPL definition, though they can signal implantation problems worth exploring.

How Common Is This

Recurrent pregnancy loss affects approximately 1-2% of couples trying to conceive, making it far more common than most women realize when they are living through it in isolation. A single miscarriage, by contrast, occurs in 10-15% of recognized pregnancies. The jump to recurrent loss is a different clinical category that warrants systematic investigation.

Signs and Symptoms That Should Prompt Earlier Evaluation

Recurrent miscarriage is defined by its pattern of pregnancy loss, not by physical symptoms between pregnancies. But several signs during or between pregnancies should move your appointment timeline earlier.

During a Pregnancy Loss

• Heavy vaginal bleeding that soaks more than one pad per hour for two consecutive hours requires emergency evaluation.
• Severe one-sided pelvic pain, especially with shoulder-tip pain, may signal an ectopic pregnancy rather than a typical miscarriage. Ectopic pregnancy is life-threatening and demands immediate care.
• Fever above 38°C (100.4°F) during or after a miscarriage suggests infection and needs same-day assessment.
• Passage of grayish or white tissue, which may be products of conception, should be evaluated to confirm the loss is complete.

Between Pregnancies

These findings between losses are reasons to book a specialist appointment rather than wait:

• Irregular or very short menstrual cycles (fewer than 24 days), which may reflect poor ovarian reserve or a luteal phase defect
• Unusually heavy periods or pelvic pain that suggests fibroids or structural uterine problems
• A personal or family history of blood clots, stroke, or autoimmune conditions, which may point toward antiphospholipid syndrome (APS)
• Thyroid symptoms such as fatigue, weight change, or hair loss, because both hypothyroidism and hyperthyroidism increase miscarriage risk

When to Go to the Emergency Department

Go to an emergency department right away if you have heavy bleeding with dizziness or fainting, severe abdominal pain, or signs of infection (fever, chills, foul-smelling discharge) during any pregnancy, however early.

Causes of Recurrent Miscarriage: What the Evidence Shows

A named cause is found in roughly 50% of couples after a complete RPL workup. The other 50% are labeled unexplained RPL, which is frustrating but does not mean untreatable. Here is what is currently understood.

Chromosomal and Genetic Causes

Chromosomal abnormalities in the embryo account for approximately 50-60% of individual first-trimester losses, but their contribution to recurrent loss is proportionally lower because pure random aneuploidy would be expected to vary from pregnancy to pregnancy. Parental chromosomal rearrangements (most often balanced translocations) are found in 3-5% of couples with RPL and do significantly raise loss rates.

Maternal age is the most powerful modifier. At age 40, the per-pregnancy miscarriage rate approaches 40-50% due to rising rates of age-related aneuploidy. This is not a character flaw or a failure of your body. It is a well-documented biological reality that your doctor should explain without euphemism.

Uterine Structural Problems

Abnormalities of the uterine cavity are found in 10-15% of women with RPL. The most clinically significant include:

• Septate uterus: The most common congenital anomaly associated with RPL; surgical correction (hysteroscopic resection) is associated with improved live birth rates, though randomized trial data remain limited.
• Submucosal fibroids: Those that distort the uterine cavity impair implantation. Intramural fibroids without cavity distortion have a less certain association.
• Intrauterine adhesions (Asherman syndrome): Often a consequence of prior uterine surgery or infection; can prevent normal implantation.
• Bicornuate or unicornuate uterus: Less commonly associated with first-trimester loss but more strongly associated with second-trimester loss and preterm birth.

Antiphospholipid Syndrome

Antiphospholipid syndrome is the most important treatable cause of RPL. APS accounts for 5-20% of recurrent losses and is diagnosed when a woman has both clinical criteria (two or more pregnancy losses, or a thrombotic event) and laboratory criteria (persistently positive antiphospholipid antibodies on two tests at least 12 weeks apart). The three antibodies tested are lupus anticoagulant, anticardiolipin antibody, and anti-beta-2 glycoprotein I antibody.

Treatment with low-dose aspirin plus low-molecular-weight heparin (LMWH) during pregnancy improves live birth rates significantly in women with APS-related RPL. This is one of the clearest evidence-based interventions in RPL medicine.

Hormonal and Metabolic Causes

Thyroid disease: Both overt hypothyroidism and hyperthyroidism increase miscarriage risk. The relationship between subclinical hypothyroidism (elevated TSH with normal T4) and RPL is more contested, but ACOG recommends thyroid testing as part of the RPL workup. Many specialists treat subclinical hypothyroidism in women with RPL if TSH is above 2.5 mIU/L, though this threshold remains debated.

PCOS: Women with PCOS have a significantly elevated miscarriage rate compared with the general population, possibly driven by insulin resistance, elevated LH, or androgen excess. Metformin has been studied as an adjunct in women with PCOS and RPL; data from the PPCOS II trial (Legro et al., NEJM 2007) and subsequent analyses suggest modest benefit in reducing miscarriage risk in this population, though it is not standard of care for all women with PCOS and RPL.

Luteal phase defect: Low progesterone in the second half of the menstrual cycle has been proposed as a cause of RPL for decades, but the evidence base for progesterone supplementation is mixed. The PROMISE trial (Coomarasamy et al., NEJM 2015) found that progesterone supplementation in women with unexplained RPL did not significantly improve live birth rates overall. However, the subsequent PRISM trial (Coomarasamy et al., NEJM 2019) found a benefit specifically in women with early pregnancy bleeding, suggesting progesterone may help in a subgroup.

Diabetes: Poorly controlled diabetes (HbA1c above 6.5%) is associated with increased miscarriage risk. Well-controlled diabetes does not appear to independently raise RPL risk to the same degree.

Thrombophilias

Inherited thrombophilias such as Factor V Leiden, Prothrombin G20210A mutation, and protein S/C deficiency have been studied extensively in RPL. The evidence for a causal link is weaker than for APS, and routine treatment of inherited thrombophilia with anticoagulation to prevent miscarriage is not currently supported by randomized trial evidence. Testing may still be done as part of a full workup, particularly when there is a personal or family history of venous thromboembolism.

Immunological and Unexplained Causes

Beyond APS, the role of other immune factors in RPL (natural killer cell levels, HLA compatibility, alloimmune theories) remains poorly supported by current evidence. Treatments marketed on these theories, including intravenous immunoglobulin, intralipid infusions, and paternal leukocyte immunization, are not recommended outside of clinical trials. Be cautious of clinics offering these as standard care.

How Recurrent Miscarriage Is Diagnosed

A systematic RPL workup should follow a structured framework. No single test diagnoses all cases, and sequencing matters. Below is a practical overview of the current evidence-based diagnostic approach.

Initial Evaluation (after 2 consecutive losses)

| Test | What It Screens For | Guideline Source | |---|---|---| | Parental karyotype (both partners) | Balanced chromosomal translocations | ASRM RPL guideline | | Antiphospholipid antibodies x3 | APS | ACOG/ASRM consensus | | TSH (thyroid function) | Hypo/hyperthyroidism | ACOG | | Uterine cavity assessment (SHG or hysteroscopy) | Septum, fibroids, adhesions | ASRM | | Fasting glucose or HbA1c | Diabetes | ACOG | | Complete blood count | Anemia, platelet disorders | Routine |

Additional Testing Based on History

• Progesterone level in the luteal phase (cycle day 21 in a 28-day cycle) if luteal phase defect is suspected
• Anti-Mullerian hormone (AMH) and antral follicle count if diminished ovarian reserve is a concern, particularly in women over 35
• Inherited thrombophilia panel if there is personal or family history of VTE
• Prolactin if cycles are irregular or there are galactorrhea symptoms

Genetic Testing of Pregnancy Tissue

When a pregnancy is lost and tissue is available, preimplantation or products-of-conception (POC) chromosomal testing can identify whether aneuploidy caused that specific loss. This is not always feasible with natural losses, but it provides valuable information when available. A euploid (chromosomally normal) loss with no other identified cause points investigators toward uterine, immune, or unexplained etiologies.

How Recurrent Miscarriage Differs Across Life Stages

Your reproductive stage shapes both your risk profile and your diagnostic and treatment priorities in concrete ways.

Reproductive Years (Under 35)

Unexplained RPL is proportionally more common in younger women because random aneuploidy is less likely to explain all losses at this age. A thorough structural and immunological workup is especially worthwhile. ASRM guidelines recommend complete evaluation after two losses regardless of age.

Trying to Conceive After 35

Age-related aneuploidy becomes an increasingly important factor. Women 35-39 may benefit from discussion of preimplantation genetic testing for aneuploidies (PGT-A) during IVF cycles, though PGT-A does not improve cumulative live birth rates in all age groups. At 40 and above, per-cycle miscarriage rates of 40-50% are expected even with otherwise normal workups, and egg donation is a conversation worth having with your specialist if multiple euploid embryo transfers have also failed.

Perimenopause (Typically 45-51)

Women in perimenopause who conceive naturally face the highest chromosomal loss rates. Irregular cycles and intermittent ovulation make timing of conception more difficult. If you are perimenopausal and have had recurrent losses, a frank conversation about the role of age-related aneuploidy versus other treatable causes is essential before investing in further cycles.

PCOS at Any Age

PCOS deserves its own mention across life stages. The miscarriage-risk elevation in PCOS appears to be partially independent of age and is linked to insulin resistance and elevated LH. Optimizing insulin sensitivity before conception (through weight management where relevant, metformin, or inositol supplementation) is a reasonable pre-conception strategy discussed in detail in ASRM PCOS guidance.

Treatment Options for Recurrent Miscarriage

Treatment depends entirely on the identified cause. There is no universal treatment for RPL.

When a Cause Is Found

• APS: Low-dose aspirin (81 mg daily) from positive pregnancy test, plus LMWH (e.g., enoxaparin 40 mg subcutaneously daily) once cardiac activity is confirmed. This combination improves live birth rates to approximately 70-80% in APS-related RPL.
• Uterine septum: Hysteroscopic resection. Success rates are promising but large randomized trial data are limited.
• Thyroid disease: Levothyroxine to normalize TSH, ideally before conception.
• PCOS with insulin resistance: Metformin 500-2000 mg daily, started before conception and often continued through the first trimester.
• Parental balanced translocation: Genetic counseling; IVF with PGT-SR (preimplantation genetic testing for structural rearrangements) is an option.

Unexplained RPL

The live birth rate after unexplained RPL without treatment is approximately 65-75% in subsequent pregnancies with supportive care and close monitoring. This is genuinely reassuring data that your doctor should share with you, not downplay. Supportive care in an early pregnancy unit (regular ultrasound, emotional support, clear communication) appears to improve outcomes even without pharmacological intervention, a finding from the Brigham Women's Hospital RPL program data and replicated in several European cohort studies.

Progesterone supplementation (vaginal micronized progesterone 400 mg twice daily) may be offered to women with unexplained RPL who present with early bleeding, based on the PRISM trial subgroup analysis. Outside of that subgroup, its benefit is uncertain.

Pregnancy and Emotional Health After Recurrent Loss

Recurrent miscarriage carries a psychological burden that clinical guidelines have historically underaddressed. A 2021 study in BJOG found that women with RPL have rates of anxiety and depression comparable to women undergoing cancer treatment. Screening for anxiety, depression, and post-traumatic stress is a legitimate part of the clinical visit, not an add-on.

Pregnancy after RPL is often experienced with intense anxiety even when a subsequent pregnancy is progressing normally. Weekly early ultrasounds during the first trimester, when available, can reduce anxiety scores measurably. Ask your provider explicitly for this level of monitoring if you need it.

Who This Is and Is Not Right For: A Life-Stage Guide

Who benefits most from early specialist referral

• Any woman with 2 or more consecutive losses
• Women over 35 with even one loss accompanied by an anomalous embryonic structure or genetic finding
• Women with a known autoimmune diagnosis (lupus, Sjogren syndrome, rheumatoid arthritis) and any pregnancy loss
• Women with PCOS who have experienced two or more losses
• Women with irregular cycles, fibroids, or prior uterine surgery who have experienced any loss

Who can be reasonably reassured with watchful waiting

• Women under 35 with one uncomplicated loss, no structural or autoimmune history, and a normal subsequent menstrual cycle
• Women whose loss was confirmed to be due to a chromosomally abnormal embryo (aneuploidy on POC testing) with no other risk factors

Pregnancy and Safety Considerations

For any woman with RPL who is actively trying to conceive, several medication-related safety points are directly relevant.

Low-dose aspirin (81 mg daily) is considered safe in pregnancy for women with APS or recurrent loss and is recommended by ACOG for women at elevated risk of preeclampsia as well. It is classified as generally safe in the first trimester; the decision to continue beyond 36 weeks is made case by case.

LMWH (enoxaparin, dalteparin) does not cross the placenta and is safe for the fetus. It is the anticoagulant of choice in pregnancy for APS. Warfarin is contraindicated in the first trimester due to teratogenicity. Direct oral anticoagulants (DOACs such as rivaroxaban and apixaban) are also contraindicated in pregnancy and must not be substituted for LMWH.

Metformin is not FDA-approved for use in pregnancy but is widely used off-label in women with PCOS and RPL. Current data do not show an increased risk of birth defects, but the evidence base is observational. Women taking metformin for PCOS-related RPL should discuss continuation versus discontinuation at 8-12 weeks with their provider.

Progesterone (vaginal micronized): Approved for use in the first trimester for luteal phase support; not a teratogen; minimal systemic transfer in lactation. Not shown to harm pregnancy.

Women with APS on therapeutic anticoagulation postpartum who are breastfeeding: LMWH does not transfer meaningfully into breast milk and is compatible with lactation. Warfarin is also considered safe for lactating mothers at standard doses. DOACs should be avoided in breastfeeding women due to insufficient safety data.